Welcure Drugs (BSE: 524661) – Q1 FY25 Result Out! 📦 Revenue: ₹299.91 Cr 💰 Net Prof!t: ₹23.30 Cr 📊 EPS: ₹2.072 📈 10x jump from March prof!t of ₹2.53 Cr 🔹 Pure sourcing model – no debt, no inventory 🔹 ₹900+ Cr confirmed order book 🔹 Profit from ₹299 Cr order already booked ⚡ Stock price: just ₹12 📉 P/E < 5 vs sector avg 40+ 🔖 #WelcureDrugs #MultibaggerStock #PennyStockIndia #UndervaluedGems #SmallCapStock #StockMarketIndia #InvestSmart #ValueInvesting #WealthCreation #StockMarketNews #LongTermStocks #Q1Results #BSEIndia #StockAlert #FinancialIndependenceIndia

💥 Welcure Drugs (BSE: 524661) completed 300 cr order ✅ ₹900+ Cr sourcing orders in just 3 weeks ✅ 5% commission = ₹46 Cr revenue potential ✅ Zero debt, asset-light model 💰 Stock price just ₹12 — massively undervalued 📊 Forward P/E under 5 vs industry avg 40+ 🕒 Q1 results due soon — time to act before it flies! 🚀 📌 DYOR but this one screams multibagger potential! ⸻ 🔖 #WelcureDrugs #BSE524661 #MultibaggerStock #PennyStockIndia #UndervaluedGems #SmallCapStock #StockMarketIndia #InvestSmart #ValueInvesting #WealthCreation #StockMarketNews #LongTermStocks #Q1Results #BSEIndia #StockAlert #FinancialIndependenceIndia